Booster shot as India's pharma market grew 8.4% in FY25: Pharmarack

India's pharmaceutical market experienced an 8.4% growth in FY25, driven by positive value growth in major therapies, according to market research firm Pharmarack. The cardiac segment led with a 10.8% value growth, followed by gastrointestinal and anti-diabetic segments at 10.2% and 8%, respectively. These three segments account for 34% of the pharma market sales, contributing to a turnover of over Rs. 2,25,000 crore (US$ 25.95 billion). The domestic market also saw a 1.2% increase in unit sales. 

GSK's antibiotic drug Augmentin remained the top-selling drug with Rs. 816 crore (US$ 94.13 million) in sales, followed by USV's anti-diabetic drug Glycomet GP at Rs. 803 crore (US$ 92.63 million). Price increases primarily drove the market growth, but remarkable events in March 2025, such as the patent expiry of the diabetes molecule empagliflozin and the launch of the anti-obesity drug Mounjaro, also impacted the market. Pharmarack's vice president, Ms. Sheetal Sapale, noted that launching Mounjaro, which uses the molecule tirzepatide, is expected to boost the anti-obesity market. In March 2025, the pharma market registered a 7.5% value growth, with companies like Sun Pharma, Torrent Pharma, Intas, and Zydus posting double-digit monthly value growth. 

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.